Free Trial

CERo Therapeutics Q2 2024 Earnings Report

CERo Therapeutics logo
$2.31 -0.03 (-1.28%)
As of 04:00 PM Eastern

CERo Therapeutics EPS Results

Actual EPS
-$33.00
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

CERo Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

CERo Therapeutics Announcement Details

Quarter
Q2 2024
Time
N/A

Conference Call Resources

CERo Therapeutics Earnings Headlines

CERo Therapeutics Holdings Inc
Bill Gates’ is about to mint millionaires (again) with Stargate.
This little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrough so advanced, it’s going to make ChatGPT look like VHS. But what’s even more unbelievable? I believe it’ll make Nvidia’s meteoric rise look like a backyard bottle rocket.
CERO Stock trading halted, news pending
See More CERo Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like CERo Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on CERo Therapeutics and other key companies, straight to your email.

About CERo Therapeutics

CERo Therapeutics (NASDAQ:CERO), an immunotherapy company, focuses on advancing the development of engineered T cell therapeutics for the treatment of cancer. Its lead program in hematologic malignancies targets an Eat Me signal upregulated on B cell and myeloid tumors. The company is based in South San Francisco, California.

View CERo Therapeutics Profile

More Earnings Resources from MarketBeat